Endpoints NewsOriginal article
Roivant reports Phase 2b lupus failure for an FcRn drug
Phase 2negativeIMVT-1402Negative
AI Analysis
Summary
Roivant's IMVT-1402 (imeroprubart), an FcRn inhibitor, failed its Phase 2b clinical trial in lupus by not meeting efficacy endpoints to improve symptoms. The failure of this leading autoimmune pipeline candidate represents a significant setback for the company.
Clinical Trial Data
Phase
2b
Primary Endpoint
Not Met
Outcome Details
Phase 2b study failed to improve symptoms in lupus
Importance:7/10
Sentiment:
-0.90
Clinical_Trial_FailureAutoimmuneFcRn_InhibitorPhase_2b
Read the original article
Published by Endpoints News on September 23, 2026 2:49 PM